share_log

bluebird bio | 10-Q: Q1 2024 Earnings Report

bluebird bio | 10-Q: Q1 2024 Earnings Report

bluebird bio | 10-Q:2024财年一季报
美股SEC公告 ·  2024/09/13 16:42

Moomoo AI 已提取核心信息

bluebird bio reported Q1 2024 total revenue of $18.6 million, up from $2.4 million in Q1 2023, driven primarily by ZYNTEGLO product sales. Net loss was $69.8 million compared to net income of $18.9 million in Q1 2023. Cost of product revenue increased to $25.9 million from $5.5 million last year.Selling, general and administrative expenses rose to $46.3 million from $37.5 million, mainly due to increased headcount and professional fees. Research and development expenses decreased to $25.1 million from $41.6 million, reflecting lower manufacturing costs as commercial production is now included in inventory and cost of goods sold.The company ended the quarter with $212.0 million in cash and cash equivalents. In March 2024, bluebird secured a $175 million term loan facility with Hercules Capital, with $75 million drawn at closing. Management expects current cash to fund operations into Q1 2025, though substantial doubt exists regarding the company's ability to continue as a going concern without additional funding.
bluebird bio reported Q1 2024 total revenue of $18.6 million, up from $2.4 million in Q1 2023, driven primarily by ZYNTEGLO product sales. Net loss was $69.8 million compared to net income of $18.9 million in Q1 2023. Cost of product revenue increased to $25.9 million from $5.5 million last year.Selling, general and administrative expenses rose to $46.3 million from $37.5 million, mainly due to increased headcount and professional fees. Research and development expenses decreased to $25.1 million from $41.6 million, reflecting lower manufacturing costs as commercial production is now included in inventory and cost of goods sold.The company ended the quarter with $212.0 million in cash and cash equivalents. In March 2024, bluebird secured a $175 million term loan facility with Hercules Capital, with $75 million drawn at closing. Management expects current cash to fund operations into Q1 2025, though substantial doubt exists regarding the company's ability to continue as a going concern without additional funding.
bluebird bio公布了2024年第一季度的营业收入为1860万美元,较2023年第一季度的240万美元有所上升,主要得益于ZYNTEGLO产品的销售。净亏损为6980万美元,而2023年第一季度的净利润为1890万美元。产品收入的营业成本从去年的550万美元增加到2590万美元。销售、一般和行政费用从3750万美元上升至4630万美元,主要是由于员工人数增加和专业费用增加。研发费用从4160万美元减少至2510万美元,反映出由于商业生产现在已包含在库存和营业成本中,制造成本降低。公司在本季度末拥有现金及现金等价物21200万美元。2024年3月,bluebird获得了与海格投资的17500万美元定期贷款贷款融资,首次融资时提取了7500万美元。管理层预计当前现金将支持公司运营到2025年第一季度,但公司在没有额外融资的情况下,持续作为一个持续经营实体的能力存在重大疑虑。
bluebird bio公布了2024年第一季度的营业收入为1860万美元,较2023年第一季度的240万美元有所上升,主要得益于ZYNTEGLO产品的销售。净亏损为6980万美元,而2023年第一季度的净利润为1890万美元。产品收入的营业成本从去年的550万美元增加到2590万美元。销售、一般和行政费用从3750万美元上升至4630万美元,主要是由于员工人数增加和专业费用增加。研发费用从4160万美元减少至2510万美元,反映出由于商业生产现在已包含在库存和营业成本中,制造成本降低。公司在本季度末拥有现金及现金等价物21200万美元。2024年3月,bluebird获得了与海格投资的17500万美元定期贷款贷款融资,首次融资时提取了7500万美元。管理层预计当前现金将支持公司运营到2025年第一季度,但公司在没有额外融资的情况下,持续作为一个持续经营实体的能力存在重大疑虑。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息